Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study-Reference-Cited by-同舟云学术

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study

Published:2019-12-11 Issue:5 Volume:107 Page:1189-1199
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Biemans Vince B.C.¹²,Woude C. Janneke³,Dijkstra Gerard⁴,Meulen‐de Jong Andrea E.⁵,Oldenburg Bas⁶,Boer Nanne K.⁷⁸,Löwenberg Mark⁹,Srivastava Nidhi¹⁰,Bodelier Alexander G.L.¹¹,West Rachel L.¹²,Jansen Jeroen M.¹³,Vries Annemarie C.³,Haans Jeoffrey J.L.²,Jong Dirk J.¹,Pierik Marie J.²,Hoentjen Frank¹

Affiliation:

1. Department of Gastroenterology and Hepatology Radboud University Medical Centre Nijmegen The Netherlands

2. Department of Gastroenterology and Hepatology Maastricht University Medical Centre Maastricht The Netherlands

3. Department of Gastroenterology and Hepatology Erasmus Medical Centre Rotterdam The Netherlands

4. Department of Gastroenterology and Hepatology University Medical Centre Groningen Groningen The Netherlands

5. Department of Gastroenterology and Hepatology Leiden University Medical Centre Leiden The Netherlands

6. Department of Gastroenterology and Hepatology University Medical Centre Utrecht Utrecht The Netherlands

7. Department of Gastroenterology and Hepatology Amsterdam University Medical Centre Vrije Universiteit Amsterdam The Netherlands

8. Amsterdam Gastroenterology & Metabolism Research Institute Amsterdam The Netherlands

9. Department of Gastroenterology and Hepatology Amsterdam University Medical Centre Academic Medical Centre Amsterdam The Netherlands

10. Department of Gastroenterology and Hepatology Haaglanden Medical Centre the Hague The Netherlands

11. Department of Gastroenterology and Hepatology Amphia Hospital Breda The Netherlands

12. Department of Gastroenterology and Hepatology Franciscus Gasthuis & Vlietland Rotterdam The Netherlands

13. Department of Gastroenterology and Hepatology Onze Lieve Vrouwe Gasthuis Amsterdam The Netherlands

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1712

Reference23 articles.

1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

3. Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

4. The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

5. Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review;Frontiers in Immunology;2024-08-20

3. Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review;Scandinavian Journal of Gastroenterology;2024-04-29

4. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease;Medicina;2024-02-09

5. Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations;Journal of Crohn's and Colitis;2024-01-08